Tara Herrmann, Director of Evidence Generation (Lung Cancer) at Daiichi Sankyo, shared a post on X:
“If you told me over a decade ago that bench-to-clinic research in lung cancer would see patients with SCLC potentially living over 2 years
~50% with wt NSCLC see 5 years
AGA live 7 years
I wouldn’t have believed you
It’s all the more personal to have a friend living with lung cancer.”
Follow the latest ESMO 2025 news on OncoDaily.